| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Ubiquitin carboxyl-terminal hydrolase 2, 3.4.19.12, 41 kDa ubiquitin-specific protease, Deubiquitinating enzyme 2, Ubiquitin thioesterase 2, Ubiquitin-specific-processing protease 2, USP2, UBP41 |
| Entrez GeneID | 9099 |
| WB Predicted band size | 68.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, African Green Mouseonkey |
| Immunogen | This USP2 antibody is generated from a mouse immunized with a recombinant protein between 1-258 amino acids from human USP2. |
+ +
以下是3篇关于USP2抗体的代表性文献，供参考：
1. **文献名称**：USP2 regulates intracellular positioning of ERK–MST2 signaling complexes to control apoptotic signaling
**作者**：Priolo, C. et al.
**摘要**：研究揭示USP2通过去泛素化ERK激酶复合物调控细胞凋亡，实验中利用USP2抗体进行免疫共沉淀和亚细胞定位分析，发现其通过调控信号复合物空间分布影响癌症细胞存活。
2. **文献名称**：USP2 maintains the stability of c-Myc protein by deubiquitinating and stabilizing Aurora-A
**作者**：Shan, J. et al.
**摘要**：该文献发现USP2通过去泛素化Aurora-A激酶稳定c-Myc蛋白，促进肝癌进展。研究中采用USP2抗体进行Western blot和免疫组化验证USP2在肝癌组织中的高表达及临床相关性。
3. **文献名称**：Targeting USP2 regulation of β-catenin signaling via a novel small-molecule inhibitor in colorectal cancer
**作者**：Li, Y. et al.
**摘要**：研究开发了靶向USP2的小分子抑制剂，并证实其通过抑制β-catenin信号通路抗结直肠癌。实验中使用USP2抗体进行ChIP-seq分析，揭示USP2与Wnt通路关键基因的染色质结合作用。
*注：以上文献信息为示例性质，实际引用时建议通过PubMed或Web of Science核对原文细节。如需扩展，可关注USP2在DNA损伤修复(如与MDM2/p53相互作用)或代谢疾病中的研究。*
**Background of USP2 Antibody**
The **Ubiquitin-Specific Protease 2 (USP2)** antibody is a research tool targeting USP2. a deubiquitinating enzyme (DUB) belonging to the ubiquitin-specific protease family. USP2 regulates protein stability and function by removing ubiquitin chains from substrate proteins, thereby counteracting proteasomal degradation. It plays critical roles in cellular processes such as cell cycle progression, apoptosis, DNA repair, and signaling pathways (e.g., NF-κB and Wnt). USP2 has two major splice variants, USP2a and USP2b, differing in their N-terminal regions, which may influence substrate specificity and cellular localization.
USP2 is implicated in diseases, particularly cancer, where it can stabilize oncoproteins (e.g., MDM2. Cyclin D1) or suppress tumorigenesis by stabilizing tumor suppressors, depending on context. Dysregulation of USP2 is linked to prostate cancer, liver cancer, and glioblastoma. USP2 antibodies are essential for detecting USP2 expression, studying its interactions, and exploring its therapeutic potential. These antibodies (monoclonal or polyclonal) are validated for applications like Western blotting, immunohistochemistry, and immunoprecipitation. Specificity validation often involves knockout cell lines or siRNA-mediated USP2 knockdown. Research using USP2 antibodies aids in understanding its dual roles in cancer and identifying inhibitors for targeted therapies.
×
